Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

The Lancet Oncology

Volumn 17, Issue 7, 2016, Pages 994-1003

  Cella, David ^a   Grünwald, Viktor ^b   Nathan, Paul ^c   Doan, Justin ^d   Dastani, Homa ^d   Taylor, Fiona ^e   Bennett, Bryan ^e   DeRosa, Michael ^e   Berry, Scott ^f   Broglio, Kristine ^f   Berghorn, Elmer ^d   Motzer, Robert J ^g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c MOUNT VERNON CANCER CENTRE   (United Kingdom)

^d BRISTOL MYERS SQUIBB   (United States)

^e ADELPHI REAL WORLD   (United Kingdom)

^f BERRY CONSULTANTS   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EUROPEAN QUALITY OF LIFE 5 DIMENSIONS QUESTIONNAIRE; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY KIDNEY SYMPTOM INDEX DISEASE RELATED SYMPTOMS; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; CANCER STAGING; CARCINOMA, RENAL CELL; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; KIDNEY NEOPLASMS; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE;

EID: 84973547996     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30125-5     Document Type: Article

References (24)

1. 1 Cella, D, Bushmakin, AG, Cappelleri, JC, Charbonneau, C, Michaelson, MD, Motzer, RJ, Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma. Br J Cancer 106 (2012), 646–650.
2. 2 Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
3. 3 Cella, D, Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. Oncologist 16:suppl 2 (2011), 23–31.
4. 4 Cella, D, Michaelson, MD, Bushmakin, AG, et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer 102 (2010), 658–664.
5. 5 Cella, D, Beaumont, JL, Pazopanib in the treatment of advanced renal cell carcinoma. Ther Adv Urol 8 (2016), 61–69.
6. 6 Cella, D, Yount, S, Brucker, PS, et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 10 (2007), 285–293.
7. 7 Dolan, P, Modeling valuations for EuroQol health states. Medical Care 35 (1997), 1095–1108.
8. 8 EuroQol Group. EuroQoL-a new facility for the measurement of health-related quality of life. Health Policy 19 (1990), 199–208.
9. 9 Pickard, AS, Neary, MP, Cella, D, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes, 5, 2007, 70.
10. 10 Cella, D, Pickard, AS, Duh, MS, et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. Eur J Cancer 48 (2012), 311–323.
11. 11 Dyer, MT, Goldsmith, KA, Sharples, LS, Buxton, MJ, A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes, 8, 2010, 13.
12. 12 Cella, D, Li, JZ, Cappelleri, JC, et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 26 (2008), 3763–3769.
13. 13 Motzer, RJ, Bacik, J, Murphy, BA, Russo, P, Mazumdar, M, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002), 289–296.
14. 14 Eton, DT, Fairclough, DL, Cella, D, Yount, SE, Bonomi, P, Johnson, DH, Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 21 (2003), 1536–1543.
15. 15 Oudard, S, Elaidi, RT, Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit. Cancer Treat Rev 38 (2012), 981–987.
16. 16 Kapoor, AK, Hotte, SJ, Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma. Can Urol Assoc J 1 (2007), S28–S33.
17. 17 Takyar, S, Diaz, J, Sehgal, M, Sapunar, F, Pandha, H, First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials. Anticancer Drugs 27 (2016), 383–397.
18. 18 Lambea, J, Hinojo, C, Lainez, N, et al. Quality of life and supportive care for patients with metastatic renal cell carcinoma. Cancer Metastasis Rev 31:suppl 1 (2012), S33–S39.
19. 19 Escudier, B, Porta, C, Bono, P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 32 (2014), 1412–1418.
20. 20 Sternberg, CN, Davis, ID, Mardiak, J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28 (2010), 1061–1068.
21. 21 Novartis. Afinitor (prescribing information), 2016, Novartis, East Hanover, NJ.
22. 22 Schrag, A, Selai, C, Jahanshahi, M, Quinn, NP, The EQ-5D-a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 69 (2000), 67–73.
23. 23 Borget, I, Bonastre, J, Catargi, B, et al. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial. J Clin Oncol 33 (2015), 2885–2892.
24. 24 Wolchok, JD, Hoos, A, O'Day, S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.